Averrhoa carambola extractive inhibits breast cancer via regulating CEPT1 and LYPLA1

Liposomes have been widely exploited as a drug delivery system in treating tumors because of their advantage to enhance anti-tumor efficacy and reduce side effects.In this study,the tumor-targeted 2-dodecyl-6-methoxycyclohexa-2,5-diene-1,4-dione(DMDD,i.e.,Averrhoa carambola extractive)liposomes(HA/TN-DLP)were conducted and assessed.HA/TN-DLP showed controllable drug loading(up to 83％)with high stability.In vitro and in vivo studies showed good cell uptake behavior and high inhibition rate of breast cancer compared to free DMDD.HA/TN-DLP might be the suitable for DMDD due to its bet-ter advantages in delivery,penetrability,and targeting-tumor capability.For in vivo mouse model tests,HA/TN-DLP effectively inhibited tumor growth compared to free DMDD.Further analyses indicated that HA/TN-DLP inhibited the glycerophospholipid metabolism pathway by reducing the biosynthesis of phos-phatidylcholine and 1-acyl-sn-glycero-3-phosphocholine through regulating the expressions of CEPT1 and LYPLA1,and inhibited tumor cell growth by regulating the PI3K/Akt and NF-KB signaling pathways.In conclusion,the obviously enhanced antitumor effect further demonstrated that HA/TN-DLP may be a promising tumor-targeting agent.